2 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
Follow Endometrial: new trials by email Literature Review of Endometrial trials Research Report on Endometrial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors TS-104 - NSCLC (Non-small Cell Lung Cancer), HNSCC | Phase 1 | Recruiting | TwoStep Therapeutics, Inc. | 74 | 2026-09-02 | 2026-09-30 |
| Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer Avutometinib, defactinib, Everolimus - Phase IB, Avutometinib | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 31 | 2026-05-13 | 2026-06-29 |
Carcinoma, Non-Small-Cell Lung (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
Adnexal Diseases (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Esophageal Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Genital Diseases (1)
Everolimus (1) · defactinib (1)
M.D. Anderson Cancer Center (1) · TwoStep Therapeutics, Inc. (1)
United States (2)